Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
Authors:
Open Access
- 21 February 2011
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 16 (3) , 264-275
Abstract
Various molecular mechanisms have been implicated in the progression from hormone-sensitive to castration-resistant prostate cancer (CRPC). Novel targeted agents to treat CRPC have been developed that inhibit either androgen receptor (AR)-mediated signaling (AR antagonists and inhibitors of androgen synthesis) or non–AR-mediated signaling (inhibitors of Src, mammalian target of rapamycin, chaperone proteins, insulin-like growth factor-1 receptor, vascular endothelial growth factor, and endothelin-A receptor) pathways. However, variable efficacy has been observed in clinical trials, most likely because of the biologic heterogeneity of CRPC. To account for potential differences in disease biology, a more individualized approach to treatment, based on genomic and/or proteomic analyses of individual tumors, is being investigated. By identifying tumors with a characteristic molecular subtype and assigning treatment accordingly, it is hoped that a higher proportion of patients will benefit from targeted therapy. Additionally, lessons learned through the application of these technologies to prostate cancer may subsequently influence therapeutic development in other solid tumors.Keywords
This publication has 95 references indexed in Scilit:
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancerInvestigational New Drugs, 2009
- Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate CancerEuropean Urology, 2009
- Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation TherapyJournal of Urology, 2009
- Targeting the androgen receptor pathway in prostate cancerCurrent Opinion in Pharmacology, 2008
- Antiandrogen withdrawal in castrate‐refractory prostate cancerCancer, 2008
- RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acidThe Prostate, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2008
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004